Fintel reports that on January 30, 2025, Stifel upgraded their outlook for Edwards Lifesciences (NYSE:EW) from Hold to Buy.

The firm’s CEO cited a “very competitive” recruiting market in 2024, but forecasts a better 2025 as longer-term efforts pay ...

Stifel analysts maintained a Buy rating and a $23.00 price target for Liberty Oilfield Services (NYSE:LBRT), following the ...

Stifel Nicolaus analyst Ian Gillies maintained a Buy rating on Badger Infrastructure Solutions (BADFF – Research Report) today and set a price ...

In a report released today, Cole McGill from Stifel Nicolaus maintained a Buy rating on Hudbay Minerals (HBM – Research Report), with a price ...

Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.

The natural beauty of West Virginia will be celebrated both musically and visually in the Wheeling Symphony Orchestra’s upcoming performance, “Nature. Beauty.” Set for 2 p.m., Feb. 8, at the Capitol ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $125.6, a high estimate of $135.00, and a low estimate of $115.00. This upward trend is evident, ...

CEO Mattias Perjos said surgical perfusion has “been a struggling category” since an FDA consent decree forced Getinge off the U.S. market in 2015.